Anti-human HER2 (Trastuzumab Biosimilar)

Amount: 100ug

Product Details

This non-therapeutic biosimilar antibody features the same variable regions as the therapeutic antibody Trastuzumab, making it ideal for research applications. It specifically binds to human HER2 (human epidermal growth factor receptor 2), also known as neu peptide, CD340, ErbB-2, or p185. HER2 is a 185 kDa transmembrane glycoprotein with intrinsic tyrosine kinase activity and functions as part of multiple cell surface receptor complexes. Although HER2 lacks a known ligand, it can become constitutively active when overexpressed. HER2 acts as a proto-oncoprotein and is frequently overexpressed in various cancers—approximately 40% of human breast cancers show elevated HER2 levels. This overexpression is associated with poor prognosis, accelerated disease progression, and resistance to chemotherapy. As a result, anti-HER2 monoclonal antibody therapy has become a standard treatment for HER2-positive advanced breast cancer. Trastuzumab works by inducing an immune-mediated response that leads to HER2 internalization and downregulation. This Trastuzumab biosimilar is validated for in vitro studies and demonstrates antibody-dependent cell-mediated cytotoxicity (ADCC) against HER2-positive cells, supporting its use in HER2-targeted research applications.

Specifications

Product name: Anti-human HER2 (Trastuzumab Biosimilar) Research Grade

Species: Human

Storage condition: 4°C for short term; -20°C for long term

Note: For research use only. Not suitable for human use

Isotype: IgG1

Clonality: Monoclonal Antibody

Purity: >95% Determined by SDS-PAGE

Sterility: 0.2 µm filtration

Purification: Protein A

RRID: AB_2894726

Molecular Weight: 150 kDa